SCHEMBL20069291

SCHEMBL20069291

CCC(=O)NC1(Cc2ccccn2)CCNCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
ALOX15 P16050 2/20 0.39
RAB9A P51151 3/20 0.38
SLC6A4 P31645 2/20 0.38
CYP2D6 P10635 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A3 Q01959 1/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RET P07949 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20070610 0.86 RET (0.44) POLBSMN1; SMN2ALDH1A1GAARAB9A
SCHEMBL20070069 0.83 LMNA (0.43) LMNAPOLBSMN1; SMN2ALDH1A1ALOX15
SCHEMBL28664232 0.82 SMN1; SMN2 (0.41) MEN1KMT2APOLBSMN1; SMN2ALDH1A1
SCHEMBL20148104 0.82 RET (0.48) MEN1KMT2APOLBALDH1A1GAA
SCHEMBL20148111 0.81 RET (0.47) MEN1KMT2APOLBSMN1; SMN2ALDH1A1
SCHEMBL20070066 0.81 RET (0.47) MEN1LMNAKMT2APOLBALDH1A1
SCHEMBL20148110 0.81 CYP3A4 (0.44) MEN1KMT2APOLBSMN1; SMN2ALDH1A1
SCHEMBL28660592 0.80 CYP1A2 (0.39) KMT2APOLBSMN1; SMN2ALDH1A1RAB9A
SCHEMBL20069289 0.79 RET (0.48) MEN1LMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL28314967 0.79 RET (0.40) KMT2APOLBSMN1; SMN2ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-12-10 US disclosed
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2020-01-30 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MEN1 653/4885LMNA 1968/4885KMT2A 1112/4885
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MEN1 653/4885LMNA 1968/4885KMT2A 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.